Breaking Down SG&A Expenses: Bristol-Myers Squibb Company vs Walgreens Boots Alliance, Inc.

SG&A Expenses: Pharma vs. Retail Giants

__timestampBristol-Myers Squibb CompanyWalgreens Boots Alliance, Inc.
Wednesday, January 1, 2014569900000017992000000
Thursday, January 1, 2015500100000022400000000
Friday, January 1, 2016500200000023910000000
Sunday, January 1, 2017484900000023813000000
Monday, January 1, 2018455100000024694000000
Tuesday, January 1, 2019487100000023557000000
Wednesday, January 1, 2020766100000025436000000
Friday, January 1, 2021769000000024586000000
Saturday, January 1, 2022781400000027295000000
Sunday, January 1, 2023777200000034205000000
Monday, January 1, 2024841400000028113000000
Loading chart...

In pursuit of knowledge

A Tale of Two Giants: SG&A Expenses in the Pharmaceutical and Retail Sectors

In the ever-evolving landscape of corporate finance, understanding Selling, General, and Administrative (SG&A) expenses is crucial for evaluating a company's operational efficiency. Bristol-Myers Squibb Company, a leader in the pharmaceutical industry, and Walgreens Boots Alliance, Inc., a retail giant, offer a fascinating comparison. From 2014 to 2023, Bristol-Myers Squibb's SG&A expenses fluctuated, peaking in 2022 with a 72% increase from its 2018 low. Meanwhile, Walgreens Boots Alliance consistently reported higher SG&A expenses, reflecting its expansive retail operations. By 2023, Walgreens' SG&A expenses were approximately 3.3 times those of Bristol-Myers Squibb. This disparity highlights the contrasting business models and operational scales of these two industry leaders. Notably, data for Bristol-Myers Squibb in 2024 is missing, underscoring the dynamic nature of financial reporting.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025